Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02433158 · ClinicalTrials.gov registry record · Phase 3
Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects With Sickle Cell Disease
A Phase 3 study, sponsored by GlycoMimetics Incorporated.
- Terminated
- Registry status
- Phase 3
- Development phase
- 154
- Enrollment target
NCT02433158: Clinical Trial Phase 3 study, sponsored by GlycoMimetics Incorporated.
NCT02433158 is a Phase 3 study that was terminated before completion, run by GlycoMimetics Incorporated. The registered enrollment target is 154 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02433158, a Phase 3 study, was terminated before completion, sponsored by GlycoMimetics Incorporated.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 154 participants
- Enrollment target
Study Summary
This is an open label extension study in subjects with Sickle Cell Disease (SCD) who have completed the double blind Phase 3 study (B5201002).
Interventions
- DRUG Rivipansel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 154 participants |
| Start Date | 2015-12-16 |
| Est. Completion | 2019-11-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02433158
The ClinicalTrials.gov registry entry for NCT02433158 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 154 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlycoMimetics Incorporated, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rivipansel is the first listed.
NCT02433158 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02433158 about?
NCT02433158 is a clinical study titled "Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects With Sickle Cell Disease". This is an open label extension study in subjects with Sickle Cell Disease (SCD) who have completed the double blind Phase 3 study (B5201002).
What is the current status of trial NCT02433158?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 154 participants. The study started on 2015-12-16. Estimated completion is 2019-11-15.
What interventions are being tested in trial NCT02433158?
The interventions under investigation include: Rivipansel (DRUG).
Who is sponsoring clinical trial NCT02433158?
This trial is sponsored by GlycoMimetics Incorporated, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.